33. (NEW) The polypeptide of Claim 31, wherein said polypeptide consists of an amino acid sequence of a full-length polypeptide sequence of SEQ ID NO: 249.

34. (NEW) A purified and isolated polypeptide comprising a full length or mature amino acid sequence encoded by a human cDNA of Clone 105-037-2-0-H11-CS in ATCC accession number PTA-1218.

35. (NEW) A method of producing the polypeptide of Claim 30, comprising the steps of:
(i) culturing a host cell capable of expressing said polypeptide under conditions suitable for producing said polypeptide; and
(ii) isolating and purifying said polypeptide produced by said host cell.

36. (NEW) A method of producing the polypeptide of Claim 34, comprising the steps of:
(i) culturing a host cell capable of expressing said polypeptide under conditions suitable for producing said polypeptide; and
(ii) isolating and purifying said polypeptide produced by said host cell.

REMARKS/ARGUMENTS

Claims 2-8, 13-23, 26 and 27 have been cancelled without prejudice. Claims 1, 9-12, 24, 25, 28, 29 and newly added Claims 30-36 are pending in this application, of which Claims 30-34 are drawn to the elected group.

Applicants respectfully request examination of newly added Claims 35 and 36. Claims 35 and 36 are drawn to methods of making the polypeptides of Claims 30-34. In view of the Patent Office Group Practice of combining a method of making an elected polypeptide with the polypeptide, when the claim is not limited to polypeptides encoded by a non-elected polynucleotide, Applicants respectfully request the grouping of Claims 35 and 36 with the elected group.

Applicants respectfully submit that support for the newly added Claims 30-36 is replete throughout the specification. Specific support for the polypeptides of Claims 30-34 can be found, e.g., in the specification at pages 213-216 and in the sequence listing at page 263 and 264. Support for new Claims 30-34 can also be found, e.g., in cancelled Claims 19, 21 and 23, and in the specification at page 49, lines 2-8. Support for new Claims 35 and 36 can be found, e.g., in

cancelled Claim 14 and in the paragraph entitled "Preparation of the polypeptides of the invention" that begins at page 50, line 23 of the specification. Applicants respectfully submit that no new matter has been added.

Attached hereto is a marked-up version of the changes made to the pending claims by the current amendment. The attached page is captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE**". Also attached hereto is a clean version of the changes made to the pending claims currently under examination entitled "**CLEAN VERSION OF CLAIMS UNDER EXAMINATION WITH ENTRY OF THE PRESENT AMENDMENT**".

Applicants respectfully submit that the present application is fully in condition for allowance and such action is earnestly solicited. If any questions remain, the Examiner is invited to contact the undersigned to resolve such questions in a timely manner. Please charge any additional fees, or credit overpayment to Deposit Account No. 50-1181.

Respectfully submitted,

GENSET CORPORATION

Date: 22 Jul, 2002 By: _____

John Lucas, Ph.D., J.D.
Reg. No. 43,373

10665 Sorrento Valley Road
San Diego, CA 92121-1609

Telephone: (868) 597-2600
Facsimile: (858) 597-2601
e-mail: john.lucas@genxy.com

Certificate of Mailing

Date of Deposit: July 23, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, on the Date of Deposit shown above, postage prepaid and in an envelope addressed to the Assistant Commissioner for Patents, Box Non Fee Amendment, Washington, D.C. 20231.

_____
Signature

C M McClure
_____
Typed or Printed Name of Person Signing Certificate

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claims 2-8, 13-23, 26 and 27 have been canceled.

Following claims 30-36 have been added:

30. (NEW) A purified and isolated polypeptide comprising an amino acid sequence of a mature polypeptide sequence of SEQ ID NO: 249.

31. (NEW) The polypeptide of Claim 30, wherein said polypeptide comprises an amino acid sequence of a full-length polypeptide sequence of SEQ ID NO: 249.

32. (NEW) The polypeptide of Claim 30, wherein said polypeptide consists of an amino acid sequence of a mature polypeptide sequence of SEQ ID NO: 249.

33. (NEW) The polypeptide of Claim 31, wherein said polypeptide consists of an amino acid sequence of a full-length polypeptide sequence of SEQ ID NO: 249.

34. (NEW) A purified and isolated polypeptide comprising a full length or mature amino acid sequence encoded by a human cDNA of Clone 105-037-2-0-H11-CS in ATCC accession number PTA-1218.

35. (NEW) A method of producing the polypeptide of Claim 30, comprising the steps of:
(i) culturing a host cell capable of expressing said polypeptide under conditions suitable for producing said polypeptide; and
(ii) isolating and purifying said polypeptide produced by said host cell.

36. (NEW) A method of producing the polypeptide of Claim 34, comprising the steps of:
(i) culturing a host cell capable of expressing said polypeptide under conditions suitable for producing said polypeptide; and
(ii) isolating and purifying said polypeptide produced by said host cell.

CLEAN VERSION OF CLAIMS UNDER EXAMINATION WITH ENTRY OF THE PRESENT AMENDMENT

1. An isolated polynucleotide, said polynucleotide comprising a nucleic acid sequence encoding:
   i) a polypeptide comprising an amino acid sequence having at least about 80% identity to any one of the sequences shown as SEQ ID NOs:242-482 or any one of the sequences of polypeptides encoded by the clone inserts of the deposited clone pool; or
   ii) a biologically active fragment of said polypeptide.

9. An expression vector comprising the polynucleotide of claim 8.

10. A host cell recombinant for the polynucleotide of claim 1.

11. A non-human transgenic animal comprising the host cell of claim 10.

12. A method of making a GENSET polypeptide, said method comprising
   a) providing a population of host cells comprising the polynucleotide of claim 8; and
   b) culturing said population of host cells under conditions conducive to the production of said polypeptide within said host cells.

24. An antibody that specifically binds to the polypeptide of claim 19.

25. A method of determining whether a GENSET gene is expressed within a mammal, said method comprising the steps of:
   a) providing a biological sample from said mammal
   b) contacting said biological sample with either of:
      i) a polynucleotide that hybridizes under stringent conditions to the polynucleotide of claim 1; or
      ii) a polypeptide that specifically binds to the polypeptide of claim 19; and

c) detecting the presence or absence of hybridization between said polynucleotide and an RNA species within said sample, or the presence or absence of binding of said polypeptide to a protein within said sample;

wherein a detection of said hybridization or of said binding indicates that said GENSET gene is expressed within said mammal.

28. A method of determining whether a mammal has an elevated or reduced level of GENSET gene expression, said method comprising the steps of :

a) providing a biological sample from said mammal; and

b) comparing the amount of the polypeptide of claim 19, or of an RNA species encoding said polypeptide, within said biological sample with a level detected in or expected from a control sample;

wherein an increased amount of said polypeptide or said RNA species within said biological sample compared to said level detected in or expected from said control sample indicates that said mammal has an elevated level of said GENSET gene expression, and wherein a decreased amount of said polypeptide or said RNA species within said biological sample compared to said level detected in or expected from said control sample indicates that said mammal has a reduced level of said GENSET gene expression.

29. A method of identifying a candidate modulator of a GENSET polypeptide, said method comprising :

a) contacting the polypeptide of claim 18 with a test compound; and

b) determining whether said compound specifically binds to said polypeptide;

wherein a detection that said compound specifically binds to said polypeptide indicates that said compound is a candidate modulator of said GENSET polypeptide.

30. A purified and isolated polypeptide comprising an amino acid sequence of a mature polypeptide sequence of SEQ ID NO: 249.

31. The polypeptide of Claim 30, wherein said polypeptide comprises an amino acid sequence of a full-length polypeptide sequence of SEQ ID NO: 249.

32. The polypeptide of Claim 30, wherein said polypeptide consists of an amino acid sequence of a mature polypeptide sequence of SEQ ID NO: 249.

33. The polypeptide of Claim 31, wherein said polypeptide consists of an amino acid sequence of a full-length polypeptide sequence of SEQ ID NO: 249.

34. A purified and isolated polypeptide comprising a full length or mature amino acid sequence encoded by a human cDNA of Clone 105-037-2-0-H11-CS in ATCC accession number PTA-1218.

35. A method of producing the polypeptide of Claim 30, comprising the steps of:

(i) culturing a host cell capable of expressing said polypeptide under conditions suitable for producing said polypeptide; and

(ii) isolating and purifying said polypeptide produced by said host cell.

36. A method of producing the polypeptide of Claim 34, comprising the steps of:

(i) culturing a host cell capable of expressing said polypeptide under conditions suitable for producing said polypeptide; and

(ii) isolating and purifying said polypeptide produced by said host cell.